Company* |
Company | Type/Product Area | Terms/Details (Date) |
Metabolic |
David Summers and T.W. Owen |
Exclusive license agreement for technologies relating to the use of fungi, plants and/ or animals for the production of anti-inflammatory and analgesic products for treating inflammatory diseases |
Worldwide licenses were gained in exchange for 2.5M shares to the two technology developers (5/7) |
Phyton |
The Dow Chemical Co. |
Phyton acquired a technology and intellectual property platform for the engineering of glycosylation in pharmaceutical protein products, namely the humanizing of monoclonal antibodies |
Financial terms were not disclosed (5/3) |
Reliance |
MPM Capital LP BioVentures IV |
Partnership to build India's life sciences sector, with Reliance becoming a limited partner in MPM |
The deal will target a portion of the fund's international allocation to invest in emerging life science companies in India (4/26) |
| Notes: | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
| OTC BB = Over-the-Counter Bulletin Board. | |||
